Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Clearmind Medicine (CMND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Clearmind Medicine is the larger company by market cap ($1.3 million vs $982,950), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | CMND |
|---|---|---|
| Share price | $1.88 | $2.63 |
| Market cap | $982.95K | $1.33M |
| 1-day change | -3.85% | -17.68% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $509.89 | $-461.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-3.86M |
| 52-week high | $357.60 | $649.60 |
| 52-week low | $1.85 | $2.63 |
| Distance from 52-week high | -99.48% | -99.60% |
| Analyst consensus | none | — |
| Avg. price target upside | +375.20% | — |
| Average volume | 618.91K | 55.57K |
| Shares outstanding | 524.24K | 507.40K |
| Employees | 11 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Clearmind Medicine
CMND stock →Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
Health Care · Biotechnology: Pharmaceutical Preparations
BDRX vs CMND FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Clearmind Medicine?
Clearmind Medicine (CMND) is larger, with a market capitalization of $1.33M compared with $982.95K for Biodexa Pharmaceuticals American Depositary Shs (BDRX).
Are Biodexa Pharmaceuticals American Depositary Shs and Clearmind Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.